Evidence map›Paper›PMID 42489754›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients.

Ye Qiu, Wu-Shu Chen, Zheng-Tu Li, Shao-Qiang Li, Yan Wang, Yang-Qing Zhan, Feng Ye

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ye Qiu *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, 510120, China.
Wu-Shu Chen *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, 510120, China.
Zheng-Tu Li *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, 510120, China.
Shao-Qiang LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, 510120, China.
Yan WangState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, 510120, China.
Yang-Qing ZhanState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, 510120, China. zhan071119@163.com.
Feng YeState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Xi Road, Guangzhou, 510120, China. tu276025@gird.cn.

Funding

Natural Science Foundation of Guangxi Province 2021GXNSFBA220064the China Postdoctoral Science Foundation No. 2023M730801the National Key Research and Development Program of China 2023ZD0506200 & 2023ZD0506204the National Natural Science Foundation of China NSFC82202544 & NSFC82270007the Science and Technology Program of Guangzhou 202201020537the State Key Laboratory of Respiratory Diseases SKLRD- Z-202019
6 · The paper itself

Abstract

backgroundIsavuconazole (ISA), voriconazole (VCZ), and amphotericin B and its derivatives (AMB) are broad-spectrum antifungal drugs. However, there is no comparison of the effectiveness and safety of ISA, AMB, and VCZ in invasive mold disease (IMD).

methodsWe conducted a real-world retrospective single-center observational cohort study of patients with proven or probable IMD who received ISA, AMB formulations, or VCZ. The primary outcome was 42-day all-cause mortality; secondary outcomes included 84-day all-cause mortality, in-hospital clinical response, and treatment-related adverse events.

resultsA total of 299 patients were included: 40 in the ISA group, 33 in the AMB group, and 226 in the VCZ group. Crude 42-day mortality was 5.0%, 24.2%, and 12.8%, respectively, and crude 84-day mortality was 7.5%, 36.4%, and 17.3%, respectively. After adjustment for major baseline and pathogen imbalances, ISA was associated with lower 42-day mortality than VCZ (adjusted OR 0.07 (95% CI 0.01-0.62), p = 0.017) and lower 84-day mortality (adjusted HR 0.18 (95% CI 0.04-0.75), p = 0.019), whereas AMB was not significantly different from VCZ. ISA was also associated with lower rates of renal and hepatic adverse events than AMB formulations.

conclusionsIn this retrospective cohort, ISA was associated with lower adjusted mortality than VCZ. ISA associated with favorable clinical outcomes and an acceptable safety profile in real-world IMD practice.

trial registrationClinical trial number: not applicable.

Indexed as

amphotericin Beffectiveness and safetyinvasive mold diseaseisavuconazolevoriconazole

Identifiers

PMID42489754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.